Navigation Links
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
Date:4/6/2009

y sleepy as narcoleptics and that the treatment effect for those on NUVIGIL was the largest we have seen to date. We are pleased that this positive study will allow us to file our first sNDA for an acute use of NUVIGIL."

NUVIGIL was generally well-tolerated in the study. The adverse events reported in this study of acute use are consistent with chronic use in the current NUVIGIL label. The most common adverse events in the study, observed more frequently with NUVIGIL use, included headache, anxiety, nausea, palpitations and fatigue.

Jet lag disorder is an acute circadian rhythm sleep disorder that results from rapid travel across several time zones. This disorder affects approximately 70 million American travelers annually and gradually resolves once a person adjusts to the new local time.

Circadian rhythm sleep disorders are disruptions in a person's internal body clock, which controls sleep patterns. When the internal body clock is disrupted, certain symptoms may develop affecting a person's ability to sleep, stay awake and function normally. Circadian rhythm sleep disorders can be caused by many factors, including shift work, time zone changes and medications.

Cephalon is preparing to launch NUVIGIL, the longer-lasting isomer of modafinil, in the third quarter of 2009. NUVIGIL is not approved for the treatment of jet lag disorder or its associated symptoms. The U.S. Food and Drug Administration-approved prescribing information for NUVIGIL, including bolded warnings, is available at www.NUVIGIL.com.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of many unique products in four core therapeutic areas: central nervous system, inflammatory diseases, pain and oncology. A member of
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cephalon Announces Positive Results From a Phase Two Study of NUVIGIL in Bipolar Depression
2. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
3. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
4. Journal of Clinical Oncology Publishes Study of Cephalon Medication TREANDA Plus Rituximab in Relapsed Non-Hodgkins Lymphoma
5. Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkins Lymphoma
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
8. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
9. Schering-Plough Announces Results of the Early ACS Trial
10. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
11. Lilly Announces Inconclusive Phase II Study Results for mGlu2/3 at the International Congress on Schizophrenia Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
(Date:4/17/2014)... YORK April 17, 2014 EcoHealth Alliance, a ... health issues, published a comprehensive review today examining the ... Marburg virus. The review calls for improved global surveillance ... as the recent outbreak of Ebola in West Africa ... the countries of Guinea and Liberia. According to ...
(Date:4/17/2014)... Population Council scientists and their partners have found that ... prevent the transmission of multiple sexually transmitted infections (STIs) ... herpes simplex virus 2 (HSV-2), and human papillomavirus (HPV). ... the gel is effective against multiple strains of HIV, ... against all three viruses of at least eight hours ...
(Date:4/17/2014)... 40 years away from a food shortage that will ... a top scientist at the U.S. Agency for International ... production will be limited on a global scale by ... Fred Davies, senior science advisor for the agency,s bureau ... destabilizing by 2050 as energy issues are today.", Davies, ...
(Date:4/17/2014)... University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work has ... as a Fellow of the European Academy of Cancer ... an independent advisory body of highly distinguished oncologists and ... suffering caused by cancer in Europe. , Professor Johnston, ... Ireland move from the bottom of the UK league ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research ... their annual Founders Dinner for their support of TGen,s ... took place March 28 in Scottsdale. , Catherine Ivy, ... Foundation, received TGen,s John S. McCain Leadership Award, named ...
Breaking Medicine News(10 mins):Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... Southern California Celebrity Gala, COSTA MESA, Calif., Aug. ... a major fundraiser to benefit,families affected by autism with ... McCarthy and Armstrong host the celebrity-packed evening Ante ... in Dana Point, California on,Friday, October 3, 2008. Joining ...
... MIAMI, Aug. 5 The National Parkinson,Foundation (NPF) ... programs,dedicated to Parkinson,s disease research, care and outreach ... network of 44,centers of excellence, 10 comprehensive care ... reaches more than 50,000 patients with,Parkinson,s disease and ...
... for Executive Communication, Training and Disaster ... ... (OTC,BB: TNXI), a leading IP solutions provider offering telepresence and VoIP,services ... been selected by St. Vincent Catholic Medical,Centers of New York for ...
... The Procter & Gamble,Company (NYSE: PG ) announced net ... to $21.3 billion and nine percent net sales growth for ... percent for both,the quarter and the fiscal year. This marks ... top-line growth at or above the,company,s targets., Diluted net ...
... Toronto Stock Exchange Symbol: CYT, MONTREAL, Aug. 5 ... products to treat cardiac,arrhythmias, today announced financial results for ... Third Quarter Financial and Operational Highlights: - ... a 12.0% increase over comparable ...
... NANJING, China, Aug. 5 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer biotech,product ... the,quarter ended June 30, 2008., Highlights ... for the second quarter, representing ...
Cached Medicine News:Health News:Jenny McCarthy and Lance Armstrong Top Celebrity List to Raise Funds for Autism 2Health News:National Parkinson Foundation Awards $3.7 Million in Grants 2Health News:St. Vincent's Catholic Medical Centers of New York Select Telanetix Telepresence Solution 2Health News:St. Vincent's Catholic Medical Centers of New York Select Telanetix Telepresence Solution 3Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 2Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 3Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 4Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 5Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 6Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 7Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 8Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 9Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 10Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 11Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 12Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 13Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 14Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 15Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 16Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 17Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 18Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 19Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 20Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 21Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 22Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 23Health News:P&G Reports Fourth Quarter EPS of $0.92 and Operating Profit Growth of 13%, Behind Balanced 5% Organic Sales and Volume Growth 24Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 9
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Lorenz 1.0 mm titanium system provides a rigid fixation alternative for areas with high palpability and prominent bone formation. These areas include the frontal bone and the areas surrounding the or...
A unique system for secure fixation of the cranial bone flap after craniotomy. Craniofix eliminates the need for mini plates, screws, and additional drills....
1.0 mm Micro System. The Titanium Micro System is also useful in the practice of ENT, Neurosurgery and Handsurgery....
Medicine Products: